Clinical trials recruiting for Extensive-stage Small-cell Lung Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
  NCT07107490 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
  NCT07502300 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
  NCT06437509 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
  NCT07654400 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
  NCT07459634 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
  NCT07037758 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 19 locations
• A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
  NCT06807632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
  NCT07652736 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
  NCT07244016 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
  NCT06223711 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
  NCT05903092 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
  NCT06497530 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
  NCT04790253 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 225 locations
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
  NCT06217757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT07061535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
  NCT05588388 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 3 locations
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
  NCT06536868 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
  NCT05874401 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Extensive-stage Small-cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Extensive-stage Small-cell Lung Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.